ARTV Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $29,999,976.00
Insider Selling (Last 12 Months): $0.00

Artiva Biotherapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Artiva Biotherapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal Insider BuyingTotal Insider Selling

Artiva Biotherapeutics Share Price & Price History

Current Price: $10.58
Price Change: Price Decrease of -0.02 (-0.19%)
As of 01/7/2025 05:00 PM ET

This chart shows the closing price history over time for ARTV up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
FebMarAprMayJunJulAugSepOctNovDecJan$10.58Closing price on 01/07/25:

Artiva Biotherapeutics Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Artiva Biotherapeutics (NASDAQ:ARTV)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARTV by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$122Mbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$100M-$50M$0$50M$100MTotal InflowsTotal Outflows
Artiva Biotherapeutics logo
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
Read More on Artiva Biotherapeutics

Today's Range

Now: $10.58
Low: $10.49
High: $11.04

50 Day Range

MA: $11.36
Low: $9.97
High: $14.47

52 Week Range

Now: $10.58
Low: $9.68
High: $17.31

Volume

47,304 shs

Average Volume

48,276 shs

Market Capitalization

$256.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Artiva Biotherapeutics?

Artiva Biotherapeutics' top insider investors include:
  1. Yong-Jun Huh (Director)
  2. Global Strategic Fund I Venbio (Major Shareholder)
Learn More about top insider investors at Artiva Biotherapeutics.